Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial). When considering the Satsuma Pharmaceuticals Inc stock dividend history, we have taken known splits into account, such that the STSA dividend history is presented on a split-adjusted ("apples to apples") basis. Satsuma Pharmaceuticals Inc dividend history is presented both in graphical/chart form, and as a STSA dividend history data table along the right-hand column.
|
STSA Stock Dividend HistoryThe STSA dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable STSA historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the STSA dividend history record. Also see the STSA stock dividend history data table along the right-hand column below. |
|
STSA Next Dividend Date » (Projection based upon history) Quotes delayed 20 minutes |
Hold (2.50 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: STSA Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection: STSA Next Dividend Date Chart: STSA Chart - 5Yr Dividend Yield |